Company Overview

Company Overview 2017-11-01T06:45:24+00:00


Dimerix Limited is a clinical stage, biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB). The Company is focused on developing new therapeutics discovered using its proprietary drug development platform, Receptor-Heteromer Investigation Technology (HIT).

Our lead therapy DMX-200 is currently in Phase II clinical trials for chronic kidney disease and has received US Orphan Drug Designation for Focal Segmental Glomerulosclerosis (FSGS).

We also have several additional programs in our pipeline including therapeutic candidates for treatment of:

NASH (fatty liver disease)

Pre-clinical development

Ocular diseases

Early stage opportunity

Cancer fatigue

Early stage opportunity

Multiple sclerosis

Early stage opportunity

Commercial strategy and partnerships

Product Development

We intend to partner or out-license our therapeutic programs at appropriate stages of development.

Discovery Services

Dimerix also has executed on services agreements with multiple leading global pharmaceutical companies to use its Receptor-HIT technology to aid their drug discovery programs.

We are also seeking to expand our contract services business through potential partnerships with global suppliers of reagents for drug discovery, and CRO’s with other discovery offerings.

Click here to look at our most recent corporate fact sheet

Intellectual Property

Dimerix has a strong and growing patent estate that covers DMX-200 combination therapy and its Receptor-HIT Technology. Read more about our Intellectual Property


Dimerix Limited, previously known as Sun Biomedical Limited, is an ASX-listed company (ASX:DXB) with major assets in its subsidiary company, Dimerix Bioscience.

Dimerix Bioscience was established as a private company in 2004, based on technology developed at the University of Western Australia, known as Receptor-Heteromer Investigation Technology (HIT)

Dimerix Bioscience underwent conversion to a public unlisted company in June 2014 and in July 2015 became a wholly owned subsidiary of Sun Biomedical Limited through a reverse takeover. Sun Biomedical’s name was changed to Dimerix Limited in November 2015, and now trades under the ASX code: DXB.